Inhaled cromolyn sodium for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an inhaled medication called cromolyn sodium for people with advanced lung cancer (stage 3 or adenocarcinoma). The goal is to see if breathing in this drug can help control the cancer and improve outcomes. If you qualify, you may receive the treatment as part of the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have a confirmed diagnosis of lung cancer, specifically stage 3 or a type called adenocarcinoma.
- You cannot have taken part in another experimental drug study within the last month.
- You cannot have fluid buildup around your heart (called pericardial effusion).
- You cannot be allergic to the study drug, cromolyn sodium.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people with stage III lung cancer that cannot be removed with surgery. You would receive immunotherapy (to help your immune system fight cancer) plus chemotherapy first, then standard chemo-radiation, and finally more immunotherapy. The goal is to see if this sequence works better than standard treatment.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
This study tests a combination of chemotherapy and immunotherapy in people with advanced non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see how well this treatment works in patients with different levels of daily activity.
This trial studies whether inhaled (aerosol) antibiotics combined with pembrolizumab can help people with advanced non-small cell lung cancer that has grown despite standard first treatment. It aims to improve cancer control by testing this new combination in Phase 1 safety and early effectiveness.
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
Hear when a new Locally Advanced Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.